Head-to-head · WeighScore
Hims & Hers vs VevaRX
The verdict
Hims & Hers takes it — 75.6/100 to 54.7/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Hims & Hers | VevaRX |
|---|---|---|
| WeighScore | 75.6/100 | 54.7/100 |
| Grade | C | C |
| Scorecard rank | #55 | #487 |
| Semaglutide | $199/mo | $189/mo (the same page also prints $167 a month and $467 for three months) |
| Tirzepatide | Not disclosed | $467 per three months, auto-renewing (about $155.67 a month; no monthly option is offered) |
| Coverage | All 50 states | 36 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #55 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Graded #487 · C
Strengths
- Publishes an exact 36-state list by name rather than a nationwide claim it then hedges
- States what the three-month figure covers — medication, supplies and the provider visit — and includes free two- to three-day shipping
- Unlimited physician access and a 24/7 care team are described as inside the program price
- Prices its peptide products openly beside the GLP-1 lines
Where it loses points
- Tirzepatide has no monthly option: it is sold as $467 for three months on a quarterly auto-renewal with a three-month minimum
- The tirzepatide page's own arithmetic is wrong — it calls $467 equivalent to $149 a month when the figure is $155.67, which the semaglutide page states correctly
- The semaglutide page carries four prices, two of which belong to tirzepatide
- Follow-up consultations are priced separately at $299 and $399, which the program pages do not mention
- NAD+ is priced three different ways on one page, at $399, $447 and $267
- Another company's domain appears in VevaRX's own Terms, in the transaction currency clause
- The contact page FAQ is a different product's copy and gives dosing instructions for a powdered drink under the question of how to take semaglutide or tirzepatide
- Two opposite return policies are live, and no pharmacy, compounding class, clinician or medical group is named anywhere
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.